Your browser doesn't support javascript.
loading
Safety, Tolerability, and Pharmacokinetics of Senaparib, a Novel PARP1/2 Inhibitor, in Chinese Patients With Advanced Solid Tumors: A Phase I Trial.
Cao, Junning; Guo, Hongqian; Ji, Dongmei; Shen, Weina; Zhang, Shun; Hsieh, Chih-Yi; Xiong Cai, Sui; Edward Tian, Ye; Xu, Cong; Zhang, Pin; Xu, Binghe.
Affiliation
  • Cao J; Department of Medical Oncology, Fudan University Shanghai Cancer Center Shanghai, Shanghai, People's Republic of China.
  • Guo H; Department of Urology, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, People's Republic of China.
  • Ji D; Department of Medical Oncology, Fudan University Shanghai Cancer Center Shanghai, Shanghai, People's Republic of China.
  • Shen W; Department of Medical Oncology, Fudan University Shanghai Cancer Center Shanghai, Shanghai, People's Republic of China.
  • Zhang S; Department of Urology, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, People's Republic of China.
  • Hsieh CY; IMPACT Therapeutics Inc., Shanghai, People's Republic of China.
  • Xiong Cai S; IMPACT Therapeutics Inc., Shanghai, People's Republic of China.
  • Edward Tian Y; IMPACT Therapeutics Inc., Shanghai, People's Republic of China.
  • Xu C; IMPACT Therapeutics Inc., Shanghai, People's Republic of China.
  • Zhang P; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
  • Xu B; Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
Oncologist ; 28(12): e1259-e1267, 2023 Dec 11.
Article de En | MEDLINE | ID: mdl-37338150
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs / Antinéoplasiques Limites: Adult / Humans Pays/Région comme sujet: Asia Langue: En Journal: Oncologist Sujet du journal: NEOPLASIAS Année: 2023 Type de document: Article Pays de publication: Royaume-Uni
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs / Antinéoplasiques Limites: Adult / Humans Pays/Région comme sujet: Asia Langue: En Journal: Oncologist Sujet du journal: NEOPLASIAS Année: 2023 Type de document: Article Pays de publication: Royaume-Uni